Increased intestinal-fatty acid binding protein in obesity-associated type 2 diabetes mellitus.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
07
2022
accepted:
18
12
2022
entrez:
26
1
2023
pubmed:
27
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Obesity is a traditional risk factor for type 2 diabetes mellitus (T2DM). However, recent studies reported that metabolically unhealthy obesity (MUO) exerts a higher risk of developing T2DM than metabolically healthy obesity (MHO) because of its higher state of insulin resistance. This may happen due to metabolic endotoxemia through gut dysbiosis and increased intestinal permeability. Our study aimed to know the association of intestinal permeability using intestinal fatty acid-binding protein (I-FABP) with obesity-related T2DM patients in Indonesia. This was a cross-sectional study that recruited 63 participants with obesity defined using body mass index (BMI) classification for the Asia-Pacific population (BMI ≥25 kg/m2). All participants were then grouped into T2DM and non-T2DM based on American Diabetes Association (ADA) diagnostic criteria. The I-FABP levels were measured using the enzyme-linked immunosorbent assay method. The I-FABP level of T2DM group was higher compared to non-T2DM group, namely 2.82 (1.23) ng/mL vs. 1.78 (0.81) ng/mL (p<0.001; mean difference 1.033 with 95% CI 0.51-1.55). This difference was not attenuated even after adjustment for age. The fitted regression model using linear regression was: i-FABP = 1.787+1.034*(DM) (R2 = 18.20%, standardized ß = 0.442, p<0.001). This study underscores the association of intestinal permeability with T2DM in people with obesity and supports the evidence of the potential role of intestinal permeability in the pathogenesis of obesity-related T2DM.
Sections du résumé
BACKGROUND
Obesity is a traditional risk factor for type 2 diabetes mellitus (T2DM). However, recent studies reported that metabolically unhealthy obesity (MUO) exerts a higher risk of developing T2DM than metabolically healthy obesity (MHO) because of its higher state of insulin resistance. This may happen due to metabolic endotoxemia through gut dysbiosis and increased intestinal permeability. Our study aimed to know the association of intestinal permeability using intestinal fatty acid-binding protein (I-FABP) with obesity-related T2DM patients in Indonesia.
METHODS
This was a cross-sectional study that recruited 63 participants with obesity defined using body mass index (BMI) classification for the Asia-Pacific population (BMI ≥25 kg/m2). All participants were then grouped into T2DM and non-T2DM based on American Diabetes Association (ADA) diagnostic criteria. The I-FABP levels were measured using the enzyme-linked immunosorbent assay method.
RESULTS
The I-FABP level of T2DM group was higher compared to non-T2DM group, namely 2.82 (1.23) ng/mL vs. 1.78 (0.81) ng/mL (p<0.001; mean difference 1.033 with 95% CI 0.51-1.55). This difference was not attenuated even after adjustment for age. The fitted regression model using linear regression was: i-FABP = 1.787+1.034*(DM) (R2 = 18.20%, standardized ß = 0.442, p<0.001).
CONCLUSIONS
This study underscores the association of intestinal permeability with T2DM in people with obesity and supports the evidence of the potential role of intestinal permeability in the pathogenesis of obesity-related T2DM.
Identifiants
pubmed: 36701395
doi: 10.1371/journal.pone.0279915
pii: PONE-D-22-19277
pmc: PMC9879407
doi:
Substances chimiques
Fatty Acid-Binding Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0279915Informations de copyright
Copyright: © 2023 Tahapary et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
J Pathol. 2018 Oct;246(2):217-230
pubmed: 29984492
Diabetes Metab. 2017 Apr;43(2):163-166
pubmed: 27745826
World J Gastroenterol. 2019 Mar 28;25(12):1478-1491
pubmed: 30948911
Bioinformation. 2018 Dec 29;14(9):560-573
pubmed: 31223215
Int J Med Sci. 2020 Aug 27;17(15):2338-2345
pubmed: 32922199
Eur J Clin Nutr. 1998 Nov;52(11):779-83
pubmed: 9846588
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
J Diabetes Res. 2018 Sep 3;2018:3462092
pubmed: 30250849
Mol Cell Biochem. 2014 Mar;388(1-2):203-10
pubmed: 24347174
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Diabetol Metab Syndr. 2020 Apr 09;12:31
pubmed: 32292494
Nutr Metab Cardiovasc Dis. 2018 Oct;28(10):1036-1044
pubmed: 30139688
Clin Lab. 2015;61(1-2):87-91
pubmed: 25807642
J Clin Endocrinol Metab. 2011 Feb;96(2):E379-83
pubmed: 21084402
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14691-6
pubmed: 20679230
Diabet Med. 2014 May;31(5):559-63
pubmed: 24236770
Scand J Gastroenterol. 2011 Dec;46(12):1435-41
pubmed: 22029621
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Nat Rev Immunol. 2009 Nov;9(11):799-809
pubmed: 19855405
Physiol Res. 2015;64(4):537-46
pubmed: 25470519
Int J Mol Sci. 2020 Sep 03;21(17):
pubmed: 32899147
Endocr Rev. 2020 May 1;41(3):
pubmed: 32128581
Science. 2018 Mar 23;359(6382):1376-1383
pubmed: 29519916
J Diabetes Complications. 2021 Feb;35(2):107766
pubmed: 33168395